[Azacitidine (Vidaza) for the treatment of myelodysplastic syndromes]
Comite d'Avaluacio de Medicaments d'Utilitzacio Hospitalaria (CAMUH)
Record ID 32010000701
To assess the efficacy, safety and efficiency of azacitidine compared to any other treatment alternatives, including placebo, for the treatment of patients with any of the indications approved by the European Medicines Agency.
Authors' recomendations: Azacitidine improves overall survival in adult patients with MDS (grade of recommendation: B). It is the first drug commercialised in Europe with the capacity to alter the natural course of the disease.
Project Status: Completed
Year Published: 2010
URL for published report: http://www.gencat.cat/salut/depsan/units/aatrm/pdf/azacitidina_smd_aatrm_2010ca.pdf
URL for additional information: http://www.gencat.cat/salut/depsan/units/aatrm/pdf/azacitidina_recomanacions_aatrm_2010ca.pdf
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Myelodysplastic Syndromes
Organisation Name: Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address: Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name: firstname.lastname@example.org / email@example.com
Contact Email: firstname.lastname@example.org / email@example.com
Copyright: Catalan Agency for Health Technology Assessment and Research (CAHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.